An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver
Chronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. Since the last consensus conference on the management of chronic hepatitis C, major advances have warranted a review of recommended management approaches for these patients. Specif...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2012/947676 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524674648866816 |
|---|---|
| author | Robert P Myers Alnoor Ramji Marc Bilodeau Stephen Wong Jordan J Feld |
| author_facet | Robert P Myers Alnoor Ramji Marc Bilodeau Stephen Wong Jordan J Feld |
| author_sort | Robert P Myers |
| collection | DOAJ |
| description | Chronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. Since the last consensus conference on the management of chronic hepatitis C, major advances have warranted a review of recommended management approaches for these patients. Specifically, direct-acting antiviral agents with dramatically improved rates of virological clearance compared with standard therapy have been developed, and several single nucleotide polymorphisms associated with an increased probability of spontaneous and treatment-induced viral clearance have been identified. In light of this new evidence, a consensus development conference was held in November 2011; the present document highlights the results of the presentations and discussions surrounding these issues. It reviews the epidemiology of hepatitis C in Canada, preferred diagnostic testing approaches and recommendations for the treatment of chronically infected patients with the newly approved protease inhibitors (boceprevir and telaprevir), including those who have previously failed pegylated interferon and ribavirin therapy. In addition, recommendations are made regarding approaches to reducing the burden of hepatitis C in Canada. |
| format | Article |
| id | doaj-art-f6a65b6003d848cea111554a4cb2ee22 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-f6a65b6003d848cea111554a4cb2ee222025-02-03T05:47:42ZengWileyCanadian Journal of Gastroenterology0835-79002012-01-0126635937510.1155/2012/947676An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the LiverRobert P Myers0Alnoor Ramji1Marc Bilodeau2Stephen Wong3Jordan J Feld4Liver Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, CanadaDepartment of Gastroenterology, University of British Columbia, Vancouver, British Columbia, CanadaLiver Unit, Department of Medicine, University of Montreal, Montreal, Quebec, CanadaSection of Hepatology, Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, CanadaToronto Western Hospital Liver Centre, University of Toronto, Toronto, Ontario, CanadaChronic hepatitis C remains a significant medical and economic burden in Canada, affecting nearly 1% of the population. Since the last consensus conference on the management of chronic hepatitis C, major advances have warranted a review of recommended management approaches for these patients. Specifically, direct-acting antiviral agents with dramatically improved rates of virological clearance compared with standard therapy have been developed, and several single nucleotide polymorphisms associated with an increased probability of spontaneous and treatment-induced viral clearance have been identified. In light of this new evidence, a consensus development conference was held in November 2011; the present document highlights the results of the presentations and discussions surrounding these issues. It reviews the epidemiology of hepatitis C in Canada, preferred diagnostic testing approaches and recommendations for the treatment of chronically infected patients with the newly approved protease inhibitors (boceprevir and telaprevir), including those who have previously failed pegylated interferon and ribavirin therapy. In addition, recommendations are made regarding approaches to reducing the burden of hepatitis C in Canada.http://dx.doi.org/10.1155/2012/947676 |
| spellingShingle | Robert P Myers Alnoor Ramji Marc Bilodeau Stephen Wong Jordan J Feld An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver Canadian Journal of Gastroenterology |
| title | An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver |
| title_full | An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver |
| title_fullStr | An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver |
| title_full_unstemmed | An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver |
| title_short | An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver |
| title_sort | update on the management of chronic hepatitis c consensus guidelines from the canadian association for the study of the liver |
| url | http://dx.doi.org/10.1155/2012/947676 |
| work_keys_str_mv | AT robertpmyers anupdateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver AT alnoorramji anupdateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver AT marcbilodeau anupdateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver AT stephenwong anupdateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver AT jordanjfeld anupdateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver AT robertpmyers updateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver AT alnoorramji updateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver AT marcbilodeau updateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver AT stephenwong updateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver AT jordanjfeld updateonthemanagementofchronichepatitiscconsensusguidelinesfromthecanadianassociationforthestudyoftheliver |